Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
Real-time Euronext Paris  -  11:36 2022-09-30 am EDT
78.40 EUR   +0.72%
09/30Correction to Sanofi and Regeneron Pharmaceuticals Article on Sept. 28
DJ
09/30SocGen Board Said to Appoint Investment Banking Head as New Group CEO
MT
09/30SocGen picks investment banking boss Krupa as its next CEO
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sanofi trial failure halts work on breast cancer treatment amcenestrant

08/17/2022 | 01:47am EDT

Aug 17 (Reuters) - Sanofi has stopped further work on amcenestrant, a treatment once seen to have strong commercial potential in breast cancer, after a second trial failure dealt a major blow to the French healthcare company's development prospects.

The move weighed on shares and mounted pressure on Sanofi to bolster its pipeline of drug candidates as it becomes increasingly dependent on its multi-billion best seller, fast-growing eczema and asthma treatment Dupixent.

Sanofi has also fallen far behind in the race to develop COVID-19 vaccines.

A trial dubbed AMEERA-5, which was testing amcenestrant on women with newly diagnosed advanced breast cancer, was stopped early because an independent monitoring panel found no signs of it working.

The shares were down 5.7% at the close, the second-biggest loss on the French blue chip index CAC40

Separately, the plaintiff in the first lawsuit over the heartburn drug Zantac, which has also been weighing on Sanofi's shares recently, on Tuesday agreed to drop his case.

Sanofi was among a range of companies selling Zantac, which U.S. regulators pulled from the market in 2020.

Since the investor scare over Zantac, which started a week ago, Sanofi shares have dropped more than 13% to a 10-month low.

CFO Jean-Baptiste de Chatillon told Reuters the recent share price rout was compounding an undervaluation that had become a buying opportunity, pointing to future prospects of hoemophilia drug hopeful efanesoctocog alfa and on nirsevimab against certain airway infections in infants.

He said there was no merit to Zantac claims and Sanofi's share of former Zantac sales was only a fraction of that of other companies.

In March, Sanofi's shares were hit when the company announced initial disappointing amcenestrant results of a breast cancer study involving previously treated women.

The company has previously said the drug candidate's biggest commercial opportunity was as a treatment early after diagnosis.

"This was a flagship drug in pipeline and important oncology asset," wrote Credit Suisse analyst Jo Walton.

In the trial, the drug was used in combination with Pfizer's established Ibrance and compared to a different group of patients on standard hormone therapy.

Amcenestrant belongs to a class of pills known as selective oestrogen receptor degraders (SERD) to fight tumours that grow in response to oestrogen, which are estimated to account for up to 80% of all breast cancer cases.

The market opportunity has also attracted Roche and AstraZeneca, which are working on pills known as giredestrant and camizestrant, respectively.

The drugs are designed to work like AstraZeneca's established injectable breast cancer drug Faslodex.

Roche said it remained committed to developing giredestrant while AstraZeneca said it remained confident in the design of our its camizestrant trials.

(Additional reporting by Tassilo Hummel in Paris; Editing by Elaine Hardcastle and Bernadette Baum)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.11% 9944 Delayed Quote.14.59%
CAC 40 1.51% 5762.34 Real-time Quote.-20.64%
CREDIT SUISSE GROUP AG 3.87% 3.976 Delayed Quote.-55.18%
ROCHE HOLDING AG 1.00% 323.45 Delayed Quote.-14.68%
SANOFI 0.72% 78.4 Real-time Quote.-11.49%
All news about SANOFI
09/30Correction to Sanofi and Regeneron Pharmaceuticals Article on Sept. 28
DJ
09/30SocGen Board Said to Appoint Investment Banking Head as New Group CEO
MT
09/30SocGen picks investment banking boss Krupa as its next CEO
RE
09/30SANOFI : Deutsche Bank sticks Neutral
MD
09/29Regeneron - dupixent approved by fda as the first and only treatment indicated for prur..
AQ
09/28Sanofi-Regeneron's Dupixent Wins First-in-Class US FDA Nod for Chronic Skin Disorder
MT
09/28Press Release : Dupixent® (dupilumab) approved by FDA as the first and only treatment indi..
GL
09/28Press Release : Dupixent® (dupilumab) approved by FDA as the first and only treatment indi..
GL
09/28Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Pru..
PR
09/28Regeneron Pharmaceuticals, Inc. and Sanofi Announce Approval of Dupixent® by FDA as the..
CI
More news
Analyst Recommendations on SANOFI
More recommendations
Financials
Sales 2022 42 406 M 41 582 M 41 582 M
Net income 2022 8 301 M 8 140 M 8 140 M
Net Debt 2022 7 803 M 7 652 M 7 652 M
P/E ratio 2022 11,9x
Yield 2022 4,56%
Capitalization 98 318 M 96 409 M 96 409 M
EV / Sales 2022 2,50x
EV / Sales 2023 2,29x
Nbr of Employees 95 442
Free-Float 87,9%
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 78,40 €
Average target price 108,05 €
Spread / Average Target 37,8%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Director
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI-11.49%96 409
JOHNSON & JOHNSON-4.51%429 503
ELI LILLY AND COMPANY19.47%307 239
ROCHE HOLDING AG-14.68%271 055
PFIZER, INC.-25.89%245 597
ABBVIE INC.-0.88%237 296